Tysabri PDUFA date extended by FDA

A board to discuss the newly-released drug Tysabri, (formerly known as Antegren) as a treatment for Multiple Sclerosis

Tysabri PDUFA date extended by FDA

Postby MSUK » Thu Oct 20, 2011 5:06 am


Biogen Idec and Elan Corporation, plc announced that the U.S. Food and Drug Administration (FDA) has extended the initial PDUFA date for its review of the supplemental Biologics License Application (sBLA) for Tysabri(R) (natalizumab).

The sBLA was submitted in December 2010 to update the Prescribing Information for Tysabri to include anti-JC virus antibody status as a factor to help stratify the risk of progressive multifocal leukoencephalopathy (PML) in the Tysabri-treated population. The 3 month extension is a standard extension period.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1905
MS-UK - http://www.ms-uk.org/
User avatar
Family Elder
Posts: 2501
Joined: Wed Oct 14, 2009 2:00 pm


Return to Tysabri (Antegren or Natalizumab)


  • Related topics
    Last post

Who is online

Users browsing this forum: No registered users

Contact us | Terms of Service